Cara Financial Statements From 2010 to 2024

CARA Stock  USD 0.67  0  0.30%   
Cara Therapeutic financial statements provide useful quarterly and yearly information to potential Cara Therapeutic investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cara Therapeutic financial statements helps investors assess Cara Therapeutic's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cara Therapeutic's valuation are summarized below:
Gross Profit
-56.1 M
Market Capitalization
38.7 M
Enterprise Value Revenue
12.0452
Revenue
21 M
Earnings Share
(2.19)
We have found one hundred twenty available fundamental signals for Cara Therapeutic, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Cara Therapeutic prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. As of April 25, 2024, Market Cap is expected to decline to about 38.2 M. In addition to that, Enterprise Value is expected to decline to about 29.7 M

Cara Therapeutic Total Revenue

25.25 Million

Check Cara Therapeutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cara main balance sheet or income statement drivers, such as Depreciation And Amortization of 498.1 K, Interest Expense of 1 M or Selling General Administrative of 15.7 M, as well as many exotic indicators such as Price To Sales Ratio of 1.82, Dividend Yield of 0.0 or PTB Ratio of 0.67. Cara financial statements analysis is a perfect complement when working with Cara Therapeutic Valuation or Volatility modules.
  
This module can also supplement Cara Therapeutic's financial leverage analysis and stock options assessment as well as various Cara Therapeutic Technical models . Check out the analysis of Cara Therapeutic Correlation against competitors.
For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.

Cara Therapeutic Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets136.4 M125.8 M117.3 M
Slightly volatile
Short and Long Term Debt Total45.3 M43.2 M8.8 M
Slightly volatile
Other Current Liabilities7.4 M14 M6.4 M
Slightly volatile
Total Current Liabilities17.5 M25.6 M15.2 M
Slightly volatile
Total Stockholder Equity112.3 M57.1 M96.4 M
Slightly volatile
Other Liabilities20.2 M19.3 M8.9 M
Slightly volatile
Property Plant And Equipment Net8.6 M8.2 M3.7 M
Slightly volatile
Accounts Payable12.2 M11.6 M4.7 M
Slightly volatile
Cash54.8 M52.2 M24 M
Slightly volatile
Non Current Assets Total9.2 M9.7 M20.1 M
Slightly volatile
Other Assets0.860.9491.3 K
Slightly volatile
Cash And Short Term Investments104.8 M101.2 M89.8 M
Slightly volatile
Net Receivables4.2 MM1.5 M
Slightly volatile
Common Stock Total Equity33.2 K61 K30.6 K
Slightly volatile
Common Stock Shares Outstanding35.8 M54.1 M31 M
Slightly volatile
Liabilities And Stockholders Equity136.4 M125.8 M117.3 M
Slightly volatile
Non Current Liabilities Total45.3 M43.2 M9.1 M
Slightly volatile
Other Current Assets5.4 M8.2 M4.7 M
Slightly volatile
Other Stockholder Equity395.3 M742 M338.3 M
Slightly volatile
Total Liabilities72.2 M68.8 M24.1 M
Slightly volatile
Property Plant And Equipment Gross10.3 M9.9 M3.9 M
Slightly volatile
Total Current Assets112.2 M116.2 M96.2 M
Slightly volatile
Short Term Debt1.4 M2.2 M1.2 M
Slightly volatile
Common Stock35.2 K54 K30.3 K
Slightly volatile
Property Plant Equipment364.2 K383.4 K1.8 M
Slightly volatile
Current Deferred Revenue26.9 M25.6 M17 M
Slightly volatile
Net Tangible Assets155.7 M182.6 M121.3 M
Slightly volatile
Capital Surpluse525.5 M835.6 M415.5 M
Slightly volatile
Net Invested Capital54.2 M57.1 M117.4 M
Slightly volatile
Net Working Capital142.3 M90.6 M110.2 M
Slightly volatile
Capital Stock54.3 K54 K44.2 K
Slightly volatile
Capital Lease Obligations4.7 M6.1 M4.3 M
Very volatile
Non Current Liabilities Other29.7 M33.4 M36.3 M
Slightly volatile

Cara Therapeutic Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization498.1 K259 K650.8 K
Slightly volatile
Selling General Administrative15.7 M27.6 M13.6 M
Slightly volatile
Other Operating Expenses79.1 M142.5 M68.2 M
Slightly volatile
Research Development62.2 M108.4 M53.6 M
Slightly volatile
Cost Of Revenue6.1 M6.4 M29.5 M
Pretty Stable
Total Operating Expenses77.9 M136 M67.2 M
Slightly volatile
Total Revenue25.2 M21 M20.2 M
Slightly volatile
Gross Profit14.2 M14.5 M11.4 M
Slightly volatile
Interest Income5.4 M5.2 M2.3 M
Slightly volatile
Non Operating Income Net OtherM2.4 M1.3 M
Slightly volatile
Reconciled Depreciation229.3 K238 K380 K
Slightly volatile

Cara Therapeutic Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8.6 M13.7 M7.4 M
Slightly volatile
Begin Period Cash Flow67.4 M64.1 M21.5 M
Slightly volatile
Other Cashflows From Financing Activities76.6 M72.9 M16.1 M
Slightly volatile
Depreciation498.1 K259 K650.8 K
Slightly volatile
Total Cash From Financing Activities52.4 M38.2 M45.4 M
Slightly volatile
End Period Cash Flow54.8 M52.2 M24.2 M
Slightly volatile
Sale Purchase Of Stock265.9 K279.9 K27.1 M
Very volatile
Change To Netincome10.7 M20.4 M8.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.821.9188259
Very volatile
PTB Ratio0.670.70487.9009
Slightly volatile
Days Sales Outstanding66.4369.9258313
Very volatile
Book Value Per Share1.01.05422.4752
Slightly volatile
Invested Capital0.680.64950.1413
Slightly volatile
Stock Based Compensation To Revenue0.620.65482.948
Very volatile
PB Ratio0.670.70487.9009
Slightly volatile
EV To Sales1.411.4888247
Very volatile
Payables Turnover0.530.55549.8904
Slightly volatile
Sales General And Administrative To Revenue1.251.31869.2377
Very volatile
Research And Ddevelopement To Revenue4.915.168945.1071
Very volatile
Cash Per Share2.041.86832.3927
Slightly volatile
Days Payables Outstanding401657211
Slightly volatile
Current Ratio6.024.53887.0342
Pretty Stable
Tangible Book Value Per Share1.01.05422.4752
Slightly volatile
Receivables Turnover4.965.219830.7433
Slightly volatile
Graham Number6.857.20528.2712
Slightly volatile
Shareholders Equity Per Share1.01.05422.4752
Slightly volatile
Debt To Equity0.680.64950.1413
Slightly volatile
Revenue Per Share0.420.38720.4797
Slightly volatile
Debt To Assets0.310.29460.0714
Slightly volatile
Operating Cycle16723098.8604
Slightly volatile
Price Book Value Ratio0.670.70487.9009
Slightly volatile
Days Of Payables Outstanding401657211
Slightly volatile
Ebt Per Ebit0.930.97552.0736
Pretty Stable
Company Equity Multiplier1.552.20451.4406
Pretty Stable
Long Term Debt To Capitalization0.410.39380.0677
Slightly volatile
Total Debt To Capitalization0.410.39380.0989
Slightly volatile
Debt Equity Ratio0.680.64950.1413
Slightly volatile
Quick Ratio5.784.116.7492
Pretty Stable
Net Income Per E B T0.80.880.9781
Slightly volatile
Cash Ratio2.782.0392.471
Pretty Stable
Days Of Sales Outstanding66.4369.9258313
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.811.02580.995
Slightly volatile
Price To Book Ratio0.670.70487.9009
Slightly volatile
Fixed Asset Turnover2.432.56146.0108
Slightly volatile
Debt Ratio0.310.29460.0714
Slightly volatile
Price Sales Ratio1.821.9188259
Very volatile
Asset Turnover0.20.16660.1835
Very volatile
Price Fair Value0.670.70487.9009
Slightly volatile

Cara Therapeutic Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap38.2 M40.2 M343 M
Slightly volatile
Enterprise Value29.7 M31.2 M326.2 M
Slightly volatile

Cara Fundamental Market Drivers

Cash And Short Term Investments101.2 M

Cara Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cara Therapeutic Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cara Therapeutic income statement, its balance sheet, and the statement of cash flows. Cara Therapeutic investors use historical funamental indicators, such as Cara Therapeutic's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cara Therapeutic investors may use each financial statement separately, they are all related. The changes in Cara Therapeutic's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cara Therapeutic's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cara Therapeutic Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cara Therapeutic. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue25.6 M26.9 M
Cost Of Revenue6.4 M6.1 M
Total Revenue21 M25.2 M
Stock Based Compensation To Revenue 0.65  0.62 
Sales General And Administrative To Revenue 1.32  1.25 
Research And Ddevelopement To Revenue 5.17  4.91 
Capex To Revenue(0.11)(0.12)
Revenue Per Share 0.39  0.42 
Ebit Per Revenue(5.79)(6.08)

Pair Trading with Cara Therapeutic

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cara Therapeutic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cara Therapeutic will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cara Stock

  0.86VKTX Viking Therapeutics Potential GrowthPairCorr
  0.78ELEV Elevation Oncology Earnings Call This WeekPairCorr
  0.69ENVB Enveric Biosciences Financial Report 20th of May 2024 PairCorr

Moving against Cara Stock

  0.48ZURA Zura Bio Limited Financial Report 10th of May 2024 PairCorr
The ability to find closely correlated positions to Cara Therapeutic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cara Therapeutic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cara Therapeutic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cara Therapeutic to buy it.
The correlation of Cara Therapeutic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cara Therapeutic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cara Therapeutic moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cara Therapeutic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:
Check out the analysis of Cara Therapeutic Correlation against competitors.
For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Cara Stock analysis

When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Valuation
Check real value of public entities based on technical and fundamental data
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Global Correlations
Find global opportunities by holding instruments from different markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Is Cara Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.19)
Revenue Per Share
0.387
Quarterly Revenue Growth
(0.08)
Return On Assets
(0.49)
Return On Equity
(1.10)
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.